Site burden has always been a trending topic in clinical research. What is the impact on study startup? One major issue is that protocol design fails to consider site workflows. When trials are ...
SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted ...
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new research study sponsored by Tempus and ...
Hosted on MSN
Cardio Diagnostics Shares Climb Following New Clinical Study Partnership with AGEPHA Pharma
Cardio Diagnostics Holdings Inc. (NASDAQ:CDIO) saw its stock increase by 7.4% after revealing a new clinical study collaboration with AGEPHA Pharma focused on treating inflammation-driven coronary ...
Entered into an additional clinical study collaboration and supply agreement with Gilead to evaluate IDE397, IDEAYA's MAT2A inhibitor, in combination with Trodelvy, Gilead's Trop-2 directed ADC, in ...
Tempus Launches Its First Study With a Nonprofit Foundation Collaborator to Create Robust FL Dataset This multi-year study will enroll FL patients to generate a comprehensive, multi-omic dataset using ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results